Patents by Inventor Nicola Brice

Nicola Brice has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240059677
    Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts, solvates and prodrugs thereof wherein in, R1, R2, R3, L and X are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy particularly for use in treating disorders associated with nicotinic acetylcholine receptor ?6 (nAChR?6) activity.
    Type: Application
    Filed: September 10, 2021
    Publication date: February 22, 2024
    Inventors: Roland Werner Burli, Martin Teall, Nicola Brice
  • Patent number: 7879564
    Abstract: We describe a method of identifying a molecule suitable for the treatment, prophylaxis or alleviation of a GPR86 associated disease, in particular inflammatory disease or pain, the method comprising determining whether a candidate molecule is an agonist or antagonist of GPR86 polypeptide, in which the GPR86 polypeptide comprises the amino acid sequence shown in SEQ ID NO: 3 or SEQ ID NO: 5 or SEQ ID NO: 7, a fragment thereof or a sequence which is at least 90% identical thereto.
    Type: Grant
    Filed: December 21, 2006
    Date of Patent: February 1, 2011
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Nicola Brice, Mark Carlton, John Dixon, Alan Hendrick, Isabelle Malinge, Sophie Messager, Dirk Zahn
  • Publication number: 20090187996
    Abstract: The present invention relates to a method of identifying a molecule suitable for the treatment, prophylaxis or alleviation of pain, the method comprising determining whether a candidate molecule is an agonist or antagonist, including a opener, blocker or modulator, of Kv9.2 polypeptide, in which the Kv9.2 polypeptide comprises the amino acid sequence shown in SEQ ID NO:3 or SEQ ID NO:5, or a sequence which is at least 90% identical thereto.
    Type: Application
    Filed: October 29, 2007
    Publication date: July 23, 2009
    Inventors: Nicola Brice, Mark Carlton, John Dixon, Isabelle Malinge, Dirk Zahn
  • Publication number: 20090180959
    Abstract: VDCC ?-8 polypeptides comprising the amino acid sequence shown in SEQ ID NO. 3, SEQ ID NO. 5 or SEQ ID NO: 7, and homologues, variants and derivatives thereof are provided. Nucleic acids capable of encoding VDCC ?-8 polypeptide are also disclosed, in particular, those comprising the nucleic acid sequences shown in SEQ ID No. 1, SEQ ID No. 2, SEQ ID NO. 4 or SEQ ID NO: 6. These polypeptides and polynucleotides are implicated in mental illness and are useful in screening for therapeutic agents useful in treating mental illness.
    Type: Application
    Filed: September 4, 2006
    Publication date: July 16, 2009
    Inventors: John Dixon, Justin Powell, Malcolm Sheardown, Nicola Brice, Jennifer Marie Horwood, Isabelle Malinge, Haiping Liu, Kok Siu Foo
  • Publication number: 20070248545
    Abstract: We describe a method of identifying a molecule suitable for the treatment, prophylaxis or alleviation of a GPR86 associated disease, in particular inflammatory disease or pain, the method comprising determining whether a candidate molecule is an agonist or antagonist of GPR86 polypeptide, in which the GPR86 polypeptide comprises the amino acid sequence shown in SEQ ID NO: 3 or SEQ ID NO: 5 or SEQ ID NO: 7, a fragment thereof or a sequence which is at least 90% identical thereto.
    Type: Application
    Filed: December 21, 2006
    Publication date: October 25, 2007
    Inventors: Nicola Brice, Mark Carlton, John Dixon, Alan Hendrick, Isabelle Malinge, Sophie Messager, Dirk Zahn
  • Publication number: 20070166230
    Abstract: Provided are Kv9.2 polypeptides comprising the amino acid sequence shown in SEQ ID NO. 3 or SEQ ID NO: 5, and homologues, variants and derivatives thereof. Nucleic acids capable of encoding Kv9.2 polypeptide are also disclosed, in particular, those comprising the nucleic acid sequences shown in SEQ ID No. 1, SEQ ID No.2 or SEQ ID NO: 4. Methods of identifying Kv9.2 agonists and antagonists are also provided.
    Type: Application
    Filed: October 30, 2006
    Publication date: July 19, 2007
    Inventors: Nicola Brice, Mark Carlton, John Dixon, Isabelle Malinge, Dirk Zahn
  • Publication number: 20070101444
    Abstract: Provided are screens for identifying compounds capable of binding to TrpM8 polypeptide. Theses compounds can be antagonists of TrpM8 polypeptide activity. Also provided is a transgenic non-human animal having a functionally disrupted endogenous TrpM8 gene.
    Type: Application
    Filed: September 28, 2006
    Publication date: May 3, 2007
    Inventors: Nicola Brice, John Dixon, Sophie Messager, Dirk Zahn